Research programme: antigen presenting cell-based therapeutics - NexImmune

Drug Profile

Research programme: antigen presenting cell-based therapeutics - NexImmune

Alternative Names: AIM 101; AIM 102; AIM 103; AIM 104; AIM ACT

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NexImmune
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cancer; Solid tumours
  • Research Autoimmune disorders; Infections

Most Recent Events

  • 17 Oct 2017 NexImmune and The Leukemia & Lymphoma Society enter into a partnership to develop AIM ACT™ in Acute myeloid leukaemia
  • 17 Oct 2017 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) before October 2017
  • 17 Oct 2017 Preclinical trials in Solid tumours in USA (Parenteral) before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top